CagriSema vs Adipotide.

CagriSema is a fixed-combination injectable investigational obesity therapeutic developed by Novo Nordisk that co-formulates two long-acting peptide analogues in a single once-weekly subcutaneous injection: cagrilintide, a long-acting amylin receptor agonist (analogue of the pancreatic hormone amylin), and semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist already marketed for diabetes and obesity. It pairs the same semaglutide molecule found in Ozempic and Wegovy with a novel amylin analogue, making it the first amylin-plus-GLP-1 dual-hormone combination to reach late-stage clinical development for weight management.

Adipotide (FTPP, also called prohibitin-targeting peptide-1) is an experimental chimeric peptidomimetic designed to destroy the blood supply of white fat rather than act as a hormone. It was developed by Kolonin, Arap and Pasqualini and colleagues as a proof-of-concept anti-obesity agent that targets the vasculature feeding adipose tissue. Adipotide has only ever been tested in animals; it has never completed human clinical trials and is not a medicine. It is discussed here strictly as a preclinical research compound.

The two components act on complementary appetite-regulating pathways. Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and signals through hypothalamic and brainstem circuits to reduce hunger and increase satiety. Cagrilintide is an amylin analogue that engages amylin and calcitonin-family receptors, also acting on the area postrema and hypothalamus to promote satiation and reduce food intake; amylin signaling is thought to modulate leptin sensitivity and meal termination through a partly distinct mechanism from GLP-1. The rationale is that combining the two yields additive or complementary reductions in energy intake beyond either agent alone.

Adipotide links two functional parts: a homing peptide (sequence CKGGRAKDC) that binds prohibitin, a protein found in unusual abundance on the endothelial cells of white-fat blood vessels, and a pro-apoptotic sequence (a KLAKLAK-type domain) that triggers programmed cell death once internalized. By selectively killing the endothelial cells that supply fat depots, the peptide is intended to starve and shrink adipose tissue. This vascular-targeting approach is fundamentally different from appetite- or metabolism-based drugs like GLP-1 agonists. The concept was first demonstrated in rodents before testing in primates.

Unlike most "research peptides," CagriSema has substantial human Phase 3 data from the REDEFINE program. In REDEFINE 1 (Garvey et al., NEJM 2025; 68 weeks, ~3,400 adults with obesity/overweight without diabetes), CagriSema produced roughly 20% mean body-weight loss versus semaglutide alone, cagrilintide alone, and placebo. In REDEFINE 2 (Davies et al., NEJM 2025), conducted in adults with overweight/obesity and type 2 diabetes, CagriSema reduced body weight and HbA1c versus placebo, though weight loss in the diabetes population was more modest, consistent with the general pattern for incretin therapies. REDEFINE 5 (Yamauchi et al., Lancet Diabetes & Endocrinology 2026) evaluated it versus semaglutide alone in Japan and Taiwan. Importantly, in the open-label head-to-head REDEFINE 4 trial, CagriSema (~23% weight loss on the efficacy estimand) did NOT meet its primary endpoint of non-inferiority versus tirzepatide (Zepbound, ~25.5%), a notable negative result that tempers claims of clear superiority over existing dual/incretin therapies.

The original concept was shown in a mouse study by Kolonin and colleagues in Nature Medicine (2004), in which targeted ablation of adipose vasculature reduced fat mass. The most cited primate work, by Barnhart and colleagues in Science Translational Medicine (2011), treated spontaneously obese rhesus monkeys with adipotide for 28 days and reported roughly 7-15% body-weight loss along with reduced body fat on imaging and improved insulin resistance, while untreated controls were unchanged. These findings were promising but limited to small animal cohorts. Both studies share the constraints of early preclinical work: small numbers of animals, short exposure, no blinding comparable to a clinical trial, imaging and biochemical surrogates rather than clinical endpoints, and no follow-up long enough to show whether fat loss persists once treatment stops or whether ablated adipose vasculature regenerates. No completed, peer-reviewed human efficacy trials exist, and marketed or clinical human data are absent. All human-facing claims about adipotide therefore rest on animal data only. The gap is total rather than partial: there is no published human pharmacokinetic profile, no established human tolerated exposure, no efficacy signal in people, and no regulatory review of any human dataset. That places adipotide in a different category from approved obesity pharmacotherapy. Drugs such as semaglutide and tirzepatide reached approval through multi-thousand-participant randomised Phase 3 programs with blinded comparators, adjudicated safety events and, in semaglutide's case, dedicated cardiovascular outcome data, and their weight-loss estimates come from human trials rather than extrapolation from monkeys. Any comparison of adipotide's reported primate weight change with those human results is not a like-for-like comparison, and the current literature on adipotide is largely mechanistic and vascular-targeting research rather than obesity therapeutics. Nothing published to date establishes that the approach translates from rodents and monkeys to people at all.

The most common adverse events in the REDEFINE trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation, consistent with the known class effects of GLP-1 receptor agonists and amylin analogues; these were generally mild-to-moderate and most frequent during dose escalation. As with other GLP-1-based therapies, label-level concerns for the class include gallbladder events, pancreatitis risk signals, and a boxed thyroid C-cell tumor warning carried by semaglutide products (based on rodent data). Long-term safety, durability after discontinuation, and outcomes in broader real-world populations remain incompletely characterized because the compound is still investigational and only recently filed for approval. No legitimate medical use exists outside clinical trials and (pending) regulatory approval, and gray-market "research" cagrilintide/semaglutide products carry purity, sterility, and dosing-error risks.

The pivotal primate study identified dose-dependent renal toxicity, specifically renal tubular changes, as the main safety signal at doses that produced meaningful weight loss; these kidney effects were a major reason human development did not advance. That finding matters because it appeared at exposures tied to the desired effect rather than only at extreme excess, which is the pattern that most often halts a candidate before first-in-human work. Because adipotide has not been through human trials, its safety in people is unknown and unvalidated. No human dose has been shown to be tolerated, there is no characterised human adverse-event profile, no drug-interaction data, and no evidence about what monitoring would even detect harm early. A legitimate first-in-human program for a pro-apoptotic vascular-targeting agent of this kind would require intensive renal function monitoring, careful dose escalation with stopping rules, and independent safety oversight, none of which applies to informal use. Material sold online as research chemical is unregulated and not quality-controlled, meaning the identity, potency, purity, endotoxin content and sterility of the vial are unverified, and there is no manufacturer accountable for a bad batch or any channel for reporting injury. Adipotide is not approved for human use in any jurisdiction, and the combination of a known organ-toxicity signal in primates with an unregulated supply chain is the central safety consideration for this compound.

CagriSema is investigational and not approved by the FDA or EMA as of mid-2026; Novo Nordisk submitted a U.S. New Drug Application for chronic weight management on December 18, 2025, with a regulatory decision anticipated in late 2026. Its individual components have separate statuses: semaglutide is FDA-approved (e.g., Wegovy, Ozempic), while cagrilintide alone is not approved.

Adipotide is a preclinical/research compound with no FDA, EMA, or other regulatory approval for any use. It is not an approved drug or supplement, and no legitimate human therapeutic product exists. Any human use would be unapproved and unstudied.